Shares of biotechnology company Hillstream BioPharma (NASDAQ:HILS) are soaring in the pre-market session today on promising initial data from HSB-1216 for the treatment of non-small cell lung cancer (NSCLC).
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The study, evaluating the combination of HSB-1216 and pembrolizumab, demonstrated a significantly greater tumor inhibition of calu-1 cells when grown with human PBMCs.
The results gain even more significance considering NSCLC makes up for 80% to 85% of all cancer-associated cases worldwide.
Shares of the company are up nearly 90% today. This is on top of the 205% gains the stock has posted over the past month alone!
Read full Disclosure
